Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The company anticipates moving forward and developing innovative analytical methods for psychedelic research. According to the announcement, the lab has also submitted an application for a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. “Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” said Delic Labs cofounder Dr. Markus Roggen in the press release. “Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer’s license is secured.”
To view the full press release, visit https://ibn.fm/yEw1Z
About Delic Holdings
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including Ketamine Wellness Centers, the largest chain of psychedelic wellness clinics in the country; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premier psychedelic wellness event; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and effective treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.